Clik here to view.
First Patient Dosed in Phase 3 Gene Therapy Trial
The purpose of the study is to evaluate the efficacy and safety of this investigational gene therapy in patients with moderately severe to severe hemophilia A.Read more about First Patient Dosed in...
View ArticleClik here to view.
Patient Advocacy Organizations Release Blueprint to Protect Access to Care
Thirty three organizations, including NHF, urge elected officals to ensure all people living in the US have access to adequate and affordable health coverage.Read more about Patient Advocacy...
View ArticleClik here to view.
Americans Believe Government Should Require Copay Assistance Be Applied to...
86 percent of registered voters believe the government should require copay assistance to be applied to patients’ cost-sharing requirements Read more about Americans Believe Government Should Require...
View ArticleClik here to view.
Public Health Symposia Now Available on the NHF Website!
These symposia were designed to encompass critical topics with far reaching implications for our communities, including emerging and novel therapies, surveillance, and key public health-related issues...
View ArticleClik here to view.
NHF Announces 2020 Kevin Child Scholarship Winner
This scholarship is named in tribute to Kevin Child, who died of AIDS in 1989, shortly before graduating from college.Read more about NHF Announces 2020 Kevin Child Scholarship Winner
View ArticleClik here to view.
Highlights from NHF’s Virtual Insurance and Reimbursement Conference
The intensive, four-day virtual workshop provided participants with the necessary tools and resources to help the community maintain access to care.Read more about Highlights from NHF’s Virtual...
View ArticleClik here to view.
With Patient Perspectives in Mind, ICER Evaluates Hemophilia Therapies
On October 30th, 2020, the Institute for Clinical and Economic Review (ICER) held a public meeting to discuss its evidence report on therapies for hemophilia A.Read more about With Patient Perspectives...
View ArticleClik here to view.
COVID-19 Vaccines: What to Expect
Join us on Friday, November 6th at 4:00pm EDT to discuss COVID-19 Vaccines: What to Expect, with NHF President and CEO Leonard A. Valentino, MD.Read more about COVID-19 Vaccines: What to Expect
View ArticleClik here to view.
Global Dosing Hold in Fitusiran Trials Initiated by Sanofi Genzyme to...
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF).Read more about Global Dosing Hold in Fitusiran Trials...
View ArticleClik here to view.
The First National Patient Satisfaction Survey of U.S. HTCs
This undertaking represents the first-of-its kind, a nationally uniform and comprehensive patient satisfaction survey of HTC clinicians, services and care processes.Read more about The First National...
View ArticleClik here to view.
Access the World’s Largest Hemophilia Repository
The My Life, Our Future Research Repository includes the largest bank of genomic and phenotypic data about people with hemophilia.Read more about Access the World’s Largest Hemophilia Repository
View ArticleClik here to view.
COVID-19 Vaccines: What to Expect
Watch NHF President and CEO Dr Len Valentino discuss the many unanswered questions regarding a COVID 19 vaccine and what it would mean for the world.Read more about COVID-19 Vaccines: What to Expect
View ArticleClik here to view.
First National HTC Patient Satisfaction Survey: The Results Are In
The survey was designed to assess patient demographics, their satisfaction with the HTC’s core multidisciplinary care team, plus affiliated clinicians, services, and care processes.Read more about...
View ArticleClik here to view.
A Great Opportunity to Learn More About Rare Platelet and Bleeding Disorders!
This webinar explores the diagnosis and clinical management of patients with rare inherited bleeding and platelet disorders.Read more about A Great Opportunity to Learn More About Rare Platelet and...
View ArticleSmall Study Looks at Use of Epidural Analgesia During Labor in VWD Type 1
Findings such as these could begin to fill a knowledge gap as current recommendations relevant to the safe use of epidural analgesia during pregnancy in VWD patients are not well defined in the...
View ArticleClik here to view.
Supporting the Judith Graham Pool Fellowship
Investing in research that deepens our understanding of inheritable bleeding disorders and fuels new treatment options is important to NHF.Read more about Supporting the Judith Graham Pool Fellowship
View ArticleFDA Puts Clinical Hold on uniQure's Hope B Trial
The following is an excerpt from a press release from uniQure. Read the update in its entirety.Today uniQure announced a clinical hold by the U.S. Food and Drug Administration (FDA) in its phase III...
View ArticleNHF Applauds Congressional Enactment of The Hemophilia SNF Access Act
The National Hemophilia Foundation is thrilled to announce that its top legislative priority in 2020, The Hemophilia SNF Access Act, was included in the end-of-year omnibus federal spending and...
View ArticleCOVID-19 Vaccination Guidance from NHF, WFH, EAHAD, and EHC for the Bleeding...
COVID-19 vaccination guidance for people with bleeding disordersGuidance from the World Federation of Hemophilia (WFH), European Association for Haemophilia and Allied Disorders (EAHAD), European...
View ArticleCOVID-19 Vaccines and Bleeding Disorders: Frequently Asked Questions (FAQs)
NHF recognizes that individuals with bleeding disorders may have questions and concerns relevant to the new COVID-19 vaccines, including any implications specific to their conditions. The following...
View Article